Since increased EGFR expression has been found to correlate with lower sensitivity to RT and platinum drugs, and poor survival [6,8,10,12,13], it is possible that these two variants, separately and in combination, affect individual response to these treatments by modulating gene expression and possibly protein levels, and, consequently, lung cancer prognosis. The gene discussed is EGFR; the disease is lung carcinoma.